ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
34.01
-0.56 (-1.62%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.54 - 35.41
52 week 18.27 - 62.66
Open 34.47
Vol / Avg. 1.00M/2.11M
Mkt cap 3.99B
P/E     -
Div/yield     -
EPS -0.53
Shares 117.27M
Beta 1.05
Inst. own 89%
Jun 10, 2014
Isis' Annual Stockholder Meeting - 5:10PM EDT - Add to calendar
May 22, 2014
Isis Pharmaceuticals, Inc. at R&D Day - 12:00PM EDT - Add to calendar
May 5, 2014
Q1 2014 Isis Pharmaceuticals Earnings Release (Estimated) Add to calendar
Apr 29, 2014
Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2014 AAN Annual Meeting - 6:00PM EDT - Add to calendar
Apr 27, 2014
Isis Pharmaceuticals, Inc. at XIVth International Symposium on Amyloidosis Add to calendar
Apr 26, 2014
Isis Pharmaceuticals, Inc. at AAN 2014 Annual Meeting Add to calendar
Apr 9, 2014
49th Annual Meeting of the European Association for the Study of the Liver
Apr 8, 2014
Isis Pharmaceuticals, Inc. at 13th Annual Needham Healthcare Conference - Webcast
Apr 5, 2014
AACR Annual Meeting
Mar 25, 2014
Isis Pharmaceuticals, Inc. at Cambridge Cancer Science Symposium
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -57.46% -41.17%
Operating margin -47.00% -35.08%
EBITD margin - -28.44%
Return on average assets -11.26% -8.71%
Return on average equity -24.97% -21.61%
Employees 304 -
CDP Score - -

Address

2855 Gazelle Court
CARLSBAD, CA 92010
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 59
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 39
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 56
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 55
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 51
Bio & Compensation  - Reuters
Breaux B. Castleman Director
Age: 72
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters